INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

25 Jun 2024 14:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

17 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Brian Goff to its Board of Directors

14 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

02 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

02 May 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

29 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 Apr 2024 08:47:12 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

25 Apr 2024 08:45:07 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 Apr 2024 08:45:17 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 Apr 2024 08:45:05 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

17 Apr 2024 08:45:39 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

16 Apr 2024 08:45:16 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

15 Apr 2024 13:45:30 By NetDania Notify

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

18 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

22 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

15 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

14 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

31 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

04 Jan 2024 15:01:00 By Nasdaq GlobeNewswire